TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24450931

Group type: EXPERIMENTAL
Intervention: Injury Prevention Briefing (IPB) with facilitation package
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Injury Prevention Briefing (IPB) with no facilitation package
Number of subjects: 33

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 33
Study: 22260366

Group type: EXPERIMENTAL
Intervention: Postcard intervention (12 postcards sent once a month for 12 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study: 20077278

Group type: EXPERIMENTAL
Intervention: Imagery training programme
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 18727454

Group type: EXPERIMENTAL
Intervention: Eperisone 100 mg three times daily (t.i.d.)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Thiocolchicoside 8 mg twice daily (b.i.d.)
Number of subjects: 160
Study: 15779223

Group type: EXPERIMENTAL
Intervention: Intraosseous injection using 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infiltration injection using 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 0
Study: 12753879

Group type: EXPERIMENTAL
Intervention: Intensive counseling and outpatient telephone follow-up
Number of subjects: 223

Group type: COMPARATOR
Intervention: Minimal counseling
Number of subjects: 223
Study: 10607493

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ginger extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8646872

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 0.005% ointment, applied topically up to 100 gm/week, twice daily for up to four weeks
Number of subjects: 388

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 388
Study: 2025077

Group type: EXPERIMENTAL
Intervention: HF‐80
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: UF‐205
Number of subjects: 105

Group type: COMPARATOR
Intervention: Cell Saver (Cell Saver 4)
Number of subjects: 105
Study: 6390802

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (Solu-Medrol) in addition to antibiotics and early surgical intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibiotics and early surgical intervention
Number of subjects: 0
Study: 31215197

Group type: EXPERIMENTAL
Intervention: Four-week aerobic training group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 31038634

Group type: EXPERIMENTAL
Intervention: Telephone intervention (follow-up at 7, 15, and 30 days after delivery)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no telephone intervention)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 85
Study: 28964538

Group type: EXPERIMENTAL
Intervention: UD sign
Number of subjects: 101

Group type: COMPARATOR
Intervention: ABCD rule
Number of subjects: 101
Study: 25113885

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine (2 mg/kg) and glucosamine (25 mg/kg) for 8 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low-dose cyclosporine alone for 8 weeks
Number of subjects: 19
Study: 23283367

Group type: EXPERIMENTAL
Intervention: MD‐DCs pulsed with autologous heat‐inactivated whole HIV
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nonpulsed MD‐DCs
Number of subjects: 33
Study: 21628339

Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 207

Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Overall grafts
Number of subjects: 207
Study: 18434729

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10-40 mg)
Number of subjects: 1036

Group type: COMPARATOR
Intervention: Atorvastatin (10-80 mg)
Number of subjects: 1036
Study: 16413495

Group type: EXPERIMENTAL
Intervention: Cognitive therapy administered in small groups
Number of subjects: 125
Study: 12888783

Group type: EXPERIMENTAL
Intervention: Higher dose ketamine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lower dose ketamine
Number of subjects: 11
Study: 10704624

Group type: EXPERIMENTAL
Intervention: Individuals heterozygous for the 68‐bp insertion (844ins68 variant)
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Individuals homozygous for the A(2756)G transition
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Individuals with polymorphic traits (C(677)T transition)
Number of subjects: 1025
Study: 9078414

Group type: EXPERIMENTAL
Intervention: Soy fiber‐supplemented formula (Isomil DF)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Soy formula (Isomil)
Number of subjects: 44
Study: 8436706

Group type: EXPERIMENTAL
Intervention: Spontaneous pushing
Number of subjects: 32

Group type: COMPARATOR
Intervention: Directed pushing
Number of subjects: 32
Study: 3741730

Group type: EXPERIMENTAL
Intervention: Caffeine 250 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caffeine 500 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29934380

Group type: EXPERIMENTAL
Intervention: Peer intervention promoting healthy eating and physical activity, facilitated by trained peers, with 12 activities mostly based on physical activity during weekends or holidays.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Peer activities involving trained facilitators and receivers.
Number of subjects: 32
Study: 24913009

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 67
Study: 25286914

Group type: EXPERIMENTAL
Intervention: Serelaxin 30 μg/kg per day for 24 hours
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 22550156

Group type: EXPERIMENTAL
Intervention: Incomplete coronary revascularization (ICR) defined by diameter stenosis (DS) cutoffs ≥50%
Number of subjects: 2954
Study: 20129826

Group type: EXPERIMENTAL
Intervention: Hydrotubation using 50 ml of saline
Number of subjects: 213

Group type: COMPARATOR
Intervention: No hydrotubation
Number of subjects: 213
Study: 18842978

Group type: EXPERIMENTAL
Intervention: Text message reminder for appointments (Intervention group)
Number of subjects: 173

Group type: COMPARATOR
Intervention: No reminder (Control group)
Number of subjects: 173
Study: 15869692

Group type: EXPERIMENTAL
Intervention: Violent video game condition
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonviolent video game condition
Number of subjects: 48
Study: 12648865

Group type: EXPERIMENTAL
Intervention: HRT (a combination of oral conjugated estrogen 0.625 mg and medroxyprogesterone acetate 5 mg daily)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: HRT + MFP (HRT combined with oral monofluorophosphate 25 mg per day)
Number of subjects: 135

Group type: COMPARATOR
Intervention: MFP (oral monofluorophosphate 25 mg per day)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: HRT + MFP
Number of subjects: 135

Group type: COMPARATOR
Intervention: MFP
Number of subjects: 135
Study: 10488413

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily
Number of subjects: 429

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429

Group type: COMPARATOR
Intervention: Placebo/lamivudine
Number of subjects: 429
Study: 8752839

Group type: EXPERIMENTAL
Intervention: Topical phosphodiesterase inhibitor (CP80,633)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 20
Study: 1872724

Group type: EXPERIMENTAL
Intervention: 10 mg of sublingual nifedipine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 0.2 mg of clonidine per os
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 6994586

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 8

Group type: COMPARATOR
Intervention: d-amphetamine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Methysertide
Number of subjects: 8
Study: 31095287

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Durvalumab (window cohort)
Number of subjects: 174
Study: 28069320

Group type: EXPERIMENTAL
Intervention: Hypothermia (32°C‐35°C) plus standard care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 26165587

Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Retrograde intrarenal surgery
Number of subjects: 38
Study: 24176495

Group type: EXPERIMENTAL
Intervention: Early vaccination (day 5 after chemotherapy)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Late vaccination (day 16 after chemotherapy)
Number of subjects: 56
Study: 17685701

Group type: EXPERIMENTAL
Intervention: Dry-aerobic exercises
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Electrostimulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water-aerobic exercises
Number of subjects: 12

Group type: COMPARATOR
Intervention: Passive rest
Number of subjects: 12
Study: 15486392

Group type: EXPERIMENTAL
Intervention: TOF monitoring
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clinical assessment
Number of subjects: 30
Study: 11295959

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg/d)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil hydrochloride (240 mg/d)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (12.5 mg/d)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Enalapril maleate (10 mg/d)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Nifedipine and verapamil
Number of subjects: 409
Study: 9168293

Group type: EXPERIMENTAL
Intervention: Potassium supplementation
Number of subjects: 2609
Study: 8287830

Group type: EXPERIMENTAL
Intervention: Anti-thyroid therapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/day for 28 days
Number of subjects: 35
Study: 3552106

Group type: EXPERIMENTAL
Intervention: Gentamicin 80 mg IV
Number of subjects: 36

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 36
Study: 30507887

Group type: EXPERIMENTAL
Intervention: Osseodensification drilling technique
Number of subjects: 12

Group type: COMPARATOR
Intervention: Osteotome site preparation (Control)
Number of subjects: 12
Study: 28675077

Group type: EXPERIMENTAL
Intervention: Implementation of randomization procedures in school-based RCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Role of school nurses in RCTs
Number of subjects: 0
Study: 26899390

Group type: EXPERIMENTAL
Intervention: Segmental vapour ablation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard medical management
Number of subjects: 70
Study: 25204320

Group type: EXPERIMENTAL
Intervention: SWITCH intervention (n=127)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control group (n=124)
Number of subjects: 251
Study: 22902937

Group type: EXPERIMENTAL
Intervention: Treadmill program without body weight support at a comfortable speed
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional physiotherapy (three sets of exercises with mat activities, balance, gait training, and functional gross motor activities)
Number of subjects: 22
Study: 21044773

Group type: EXPERIMENTAL
Intervention: Donepezil treatment
Number of subjects: 3748

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 3748
Study: 17239689

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meta-analyses
Number of subjects: 0
Study: 15734707

Group type: EXPERIMENTAL
Intervention: Vitamin A-fortified coconut cooking oil
Number of subjects: 542

Group type: COMPARATOR
Intervention: Unfortified cooking oil
Number of subjects: 542

Group type: COMPARATOR
Intervention: No cooking oil ration
Number of subjects: 542
Study: 12139210

Group type: EXPERIMENTAL
Intervention: Oral solution (2 g metamizole)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ampoules (2 g metamizole)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Capsules (reference)
Number of subjects: 19
Study: 10460199

Group type: EXPERIMENTAL
Intervention: Nocturnal oral fat load test (OFLT) at 2200 h
Number of subjects: 9

Group type: COMPARATOR
Intervention: Diurnal oral fat load test (OFLT) at 0700 h
Number of subjects: 9
Study: 7791836

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (10-g intramuscular loading dose followed by 5 g every four hours; additional 4-g loading dose intravenously for severe preeclampsia)
Number of subjects: 2138

Group type: COMPARATOR
Intervention: Phenytoin (1000-mg loading dose infused over 1 hour, followed by 500-mg oral dose 10 hours later)
Number of subjects: 2138
Study: 2215101

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.4 mg/kg propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.6 mg/kg propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.8 mg/kg propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2.0 mg/kg propofol
Number of subjects: 60
Study: 343408

Group type: EXPERIMENTAL
Intervention: 10 mgs of diazepam (for patients <60 years) and 5 mgs (for patients >60 years)
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1-2 mgs)
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Premedication with diazepam
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Premedication and endoscopy
Number of subjects: 771
Study: 31043662

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left dlPFC
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 22
Study: 27633341

Group type: EXPERIMENTAL
Intervention: Active pharmacotherapies (specifics not provided)
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1236
Study: 25881872

Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) of piperacillin/tazobactam (11.25g/day on Day 1 followed by 9g/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intermittent bolus (IB) administration of piperacillin/tazobactam (11.25g/day on Day 1 followed by 9g/day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) of piperacillin
Number of subjects: 16
Study: 23670667

Group type: EXPERIMENTAL
Intervention: Cystic Fibrosis Questionnaire-Revised (CFQ-R) - Physical domain
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Cystic Fibrosis Questionnaire-Revised (CFQ-R) - Psychosocial domains
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Clinical variables (FEV1, exacerbation frequency, weight)
Number of subjects: 333
Study: 21872209

Group type: EXPERIMENTAL
Intervention: Radial artery graft
Number of subjects: 726

Group type: COMPARATOR
Intervention: Saphenous vein graft
Number of subjects: 726
Study: 19042058

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamins E, C, and/or beta-carotene)
Number of subjects: 134590

Group type: EXPERIMENTAL
Intervention: Single antioxidant supplementation
Number of subjects: 134590

Group type: EXPERIMENTAL
Intervention: Combination of antioxidants
Number of subjects: 134590

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134590
Study: 17719703

Group type: EXPERIMENTAL
Intervention: Immediate oral feeding
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 60
Study: 15113366

Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy with rabeprazole 20 mg b.d. plus amoxicillin 1 g b.d. for the first 5 days, followed by rabeprazole 20 mg b.d., clarithromycin 250 mg b.d. and tinidazole 500 mg b.d. (low-dose therapy)
Number of subjects: 162

Group type: COMPARATOR
Intervention: 10-day sequential therapy with rabeprazole 20 mg b.d. plus amoxicillin 1 g b.d. for the first 5 days, followed by rabeprazole 20 mg b.d., clarithromycin 500 mg b.d. (high-dose therapy)
Number of subjects: 162
Study: 11552293

Group type: EXPERIMENTAL
Intervention: Autologous endometrial coculture (n = 134)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Classic IVF (control group) (n = 82)
Number of subjects: 216
Study: 9846802

Group type: EXPERIMENTAL
Intervention: Dental rubber dam (DRD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Expanded polytetrafluoroethylene (e-PTFE)
Number of subjects: 22
Study: 7838336

Group type: EXPERIMENTAL
Intervention: Posterior fossa reconstruction (PFR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (classic approach)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 10
Study: 3048102

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (150 mg/day)
Number of subjects: 46
Study: 31913072

Group type: EXPERIMENTAL
Intervention: Deep learning method using Inception-v3 architecture CNN model on corticomedullary phase images
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Deep learning method using CNN models on different CT phases
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression analysis
Number of subjects: 159
Study: 29718931

Group type: EXPERIMENTAL
Intervention: Fitbit with reminders
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Fitbit with goal setting
Number of subjects: 138

Group type: COMPARATOR
Intervention: Fitbit only
Number of subjects: 138
Study: 27340879

Group type: EXPERIMENTAL
Intervention: Alcohol intake (≥30 g alcohol/day)
Number of subjects: 120852

Group type: EXPERIMENTAL
Intervention: Dietary folate intake
Number of subjects: 120852

Group type: EXPERIMENTAL
Intervention: Strata according to methylation index
Number of subjects: 120852

Group type: EXPERIMENTAL
Intervention: Alcohol and dietary folate intake interaction
Number of subjects: 120852
Study: 25914483

Group type: EXPERIMENTAL
Intervention: Antibiotic group (cefuroxime 1.5 g iv half an hour before and 6 h after surgery)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 409
Study: 24434093

Group type: EXPERIMENTAL
Intervention: Prolonged exposure psychotherapy
Number of subjects: 283

Group type: COMPARATOR
Intervention: Present-centered psychotherapy
Number of subjects: 283
Study: 20649626

Group type: EXPERIMENTAL
Intervention: Fenofibrate (145 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 19213352

Group type: EXPERIMENTAL
Intervention: Pishen Bingbu Recipe (PBR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (mecobalamin, vitamin B1, neurotropin, occipital-jaw band traction)
Number of subjects: 50
Study: 16823368

Group type: EXPERIMENTAL
Intervention: Professional fencers at 40%, 60%, and 80% of Pmax
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sedentary subjects at varying workloads (20%, 40%, 60%, 80% of Pmax)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Professional fencers at rest
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Professional fencers under physical load
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sedentary subjects under physical load
Number of subjects: 24
Study: 12791813

Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 70
Study: 11677198

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol (0.01 mg) plus norethisterone (2 mg) (1 tablet/d)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (1 tablet/d)
Number of subjects: 72
Study: 9126796

Group type: EXPERIMENTAL
Intervention: Diuretics (spironolactone 100-400 mg/day and furosemide 80-320 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Large-volume paracentesis plus intravenous albumin (6-8 g/l ascites removed)
Number of subjects: 26
Study: 1392697

Group type: EXPERIMENTAL
Intervention: 10 mg i.v. infusion of alendronate over 2 hours (group A, n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 mg i.v. infusion of alendronate over 24 hours (group B, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both treatments (A and B)
Number of subjects: 20
Study: 3908126

Group type: EXPERIMENTAL
Intervention: Acebutolol 400-600 mg/day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25-50 mg/day
Number of subjects: 45
Study: 31727642

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Bovine colostrum
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: N-acetyl glucosamine
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Teduglutide
Number of subjects: 225

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 225
Study: 27885682

Group type: COMPARATOR
Intervention: Sodium fluorescein (NaF) applied at various time points after AFXL exposure (0, 2, 5, 10, 30 minutes, 6, 24, and 48 hours)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sodium fluorescein (NaF) applied at 0, 2, 5, 10, and 30 minutes after AFXL exposure
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sodium fluorescein (NaF) applied later than 30 minutes after AFXL exposure
Number of subjects: 11

Group type: COMPARATOR
Intervention: Optical coherence tomography (OCT) assessment of AFXL channel dimensions
Number of subjects: 11

Group type: COMPARATOR
Intervention: Transepidermal water loss (TEWL) measurements
Number of subjects: 11
Study: 25828624

Group type: EXPERIMENTAL
Intervention: Paleo diet
Number of subjects: 24

Group type: COMPARATOR
Intervention: ADA diet
Number of subjects: 24
Study: 23786651

Group type: EXPERIMENTAL
Intervention: Goal Management Training with an errorless learning approach
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional Goal Management Training based on trial and error learning
Number of subjects: 32
Study: 21857087

Group type: EXPERIMENTAL
Intervention: bezafibrate (200 mg twice daily)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: ω‐3 fatty acids (1 g twice daily)
Number of subjects: 73

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 73
Study: 19215552

Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg) on day 1 and vaginal misoprostol (800 microg) on day 3
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vaginal misoprostol (800 microg) on days 1 and 3 (total dose 1600 microg)
Number of subjects: 100
Study: 17126406

Group type: EXPERIMENTAL
Intervention: Bipolar disorder (BP)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Creative discipline controls (CC)
Number of subjects: 153